Overview

This trial is active, not recruiting.

Condition hyperparathyroidism
Treatment far infrared radiation
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date January 2007
End date March 2009
Trial size 2 participants
Trial identifier NCT00573573, GAAD-HT-CTP1

Summary

A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Other)
far infrared radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.

Primary Outcomes

Measure
The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism.
time frame: 2 years

Secondary Outcomes

Measure
Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes
time frame: 2 years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Persons with parathyroid disease Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.
Description Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones. We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.
Trial information was received from ClinicalTrials.gov and was last updated in March 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..